US-China Biotech Deals Face Growing Complexity as Washington Expands Investment Curbs
Cross-border biotech deals between China and the United States are becoming more complicated and may face a modest slowdown due to stepped-up US efforts to restrict investment and technology transfers, according to ING Research.
Read Article